WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 1 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 7'644  7'542  7'420  7'274  7'107  6'014  4'499  3'745 
Births 156  155  154  152  149  127  100  93 
Surviving infants 156  155  153  151  149  127  99  92 
Pop. less than 5 years 772  758  735  722  705  614  483  458 
Pop. less than 15 years 2'109  2'069  2'021  1'991  1'953  1'689  1'406  1'237 
Female 15-49 years 1'803  1'785  1'764  1'735  1'702  1'503  1'096  874 

Number of reported case

(Click for retrospective incidence data for Israel)
Diphtheria
Japanese encephalitis
Measles 211  70  23  931  36  230  215 
Mumps 93  301  4'923  775  11  48 
Pertussis 2'730  2'345  1'244  1'182  2'169  452  155  19 
Polio* 11 
Rubella 54 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Israel)
Vaccine year result method % card seen                                                
BCG          75 
DTP1          96  96  97  94 
DTP3          94  96  96  93  84 
HepB_BD          100 
HepB3          97  99  97  99  96  97 
Hib3          95  94 
JapEnc         
MCV          96  98  96  98  98  97  91  81 
MCV2          95  88  92  92  96 
PCV1         
PCV3         
Pol3          95  94  95  94  94  92  93  85 
Rota1         
Rota_last         
Rubella1          96  98  97  94 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Israel)
BCG 75 
DTP1 96  96  96  96  96  96  97  94 
DTP3 94  94  94  94  96  96  93  84 
HepB3 97  97  97  99  96  97 
Hib3 93  93  93  93  93  94 
MCV 96  96  96  98  98  97  91  81 
PCV3
Pol3 95  95  95  94  94  92  93  85 
Rota_last

Number of districts in the country 15  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG Yes risk groups
DT 2, 4, 6, 12 months; Yes if Pertussis contraindicated
DTaP 2, 4, 6, 12 months; Yes
DTaPHibIPV 2, 4, 6, 12 months; Yes
HPV 10-45 years; + 1, +6 months; Yes and HPV GARDASIL from year 9 to year 49, + 2, +6 months
HepA 18, 24 months; Yes and risk groups
HepB birth; 1, 6 months; Yes and risk groups
Hib 2, 4, 6, 12 months; Yes risk groups
IPV Yes risk groups, catch up
Influenza > 6 months; Yes general population
JapEnc 0, 7, 28 days; Yes Travellers; dose at D7 depends on vaccine presentation
MMR 12 months; 6 years; Yes and risk groups
MMRV 12 months; 6 years; Yes
MenACWY Yes risk groups
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps >= 65 years; Yes risk groups
Rotavirus 2, 4, 6 months; Yes
TBE Yes Travellers
Td Yes every ten years to adult population and for tetanus prophilaxis in wound management
TdaPIPV 7 years; Yes
Tdap 14 years; Yes
Typhoid Yes Travellers
TyphoidHepA Yes Travellers
Varicella 12 months; 6 years; Yes
YF Yes Travellers

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   10 years  5 years  5 year  5 years  5 years 
Nº of districts with microplans that include activities to raise immunization coverage number 15  15  15  15  15  15  15 

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number 15  15  15  15  15  15  15 
Nº districts with DTP3 coverage >=80% number 15  15  15  15  15  15  15 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 15         
% of districts with MCV1 coverage >=95% From 0 to 100% 100       

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes         

Finance

Percentage of routine vaccines funded by Government From 0 to 100%         N.D.    100 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.